0Q1N Stock Chart & Stats
$28.11
$0.00(0.00%)
At close: 4:00 PM EDT
$28.11
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$21.83 - $30.44
Previous CloseN/A
Volume86.00
Average Volume (3M)93.85K
Market Cap
$169.85B
Enterprise Value$190.23B
Total Cash (Recent Filing)$11.70B
Total Debt (Recent Filing)$63.19B
Price to Earnings (P/E)39.4
Beta0.89
Next Earnings
Nov 03, 2026EPS Estimate
0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.76
Shares Outstanding5,699,674,000
10 Day Avg. Volume136,902
30 Day Avg. Volume93,849
Financial Highlights & Ratios
PEG Ratio-4.33
Price to Book (P/B)1.64
Price to Sales (P/S)2.26
P/FCF Ratio15.59
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue2.99
Enterprise Value/Gross Profit4.08
Enterprise Value/Ebitda14.10
Forecast
1Y Price Target
$29.62Price Target Upside5.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering23
EPS Forecast (FY)2.95
Revenue Forecast (FY)$62.23B
Bulls Say, Bears Say
Bulls Say
Underlying Revenue GrowthGrowth excluding COVID products indicates Pfizer is rebuilding its core commercial base rather than relying solely on pandemic-related demand. This broader revenue foundation can support more durable performance as established medicines, newer launches, and acquired products increasingly contribute.
Launched Product MomentumStrong growth from launched and acquired products demonstrates that Pfizer is converting business-development activity and commercial investments into meaningful sales. Continued momentum across this portfolio can help offset mature-product declines and provide a stronger platform for future earnings.
Pipeline And Oncology ProgressA successful Phase 3 result for ELREXFIO strengthens Pfizer's oncology pipeline and supports potential expansion in multiple myeloma. The planned regulatory submissions could extend the product's commercial opportunity, although overall-survival follow-up remains ongoing.
Bears Say
Elevated LeverageHigher leverage reduces financial flexibility compared with Pfizer's earlier position and increases the importance of sustained cash generation. It can constrain acquisitions, shareholder returns, and investment choices while debt remains elevated relative to the company's reduced earnings base.
Loss-of-Exclusivity PressureUpcoming loss-of-exclusivity events create a durable transition risk because generic or biosimilar competition can erode established-product revenue. Maintaining leverage during that period may limit Pfizer's ability to absorb declines while funding replacement products and pipeline development.
Earnings VolatilityThe sharp decline from earlier peak earnings shows that Pfizer's profit base remains volatile and materially below prior highs. Lower and less predictable earnings can weaken internal funding capacity, reduce resilience during product transitions, and make sustained returns more difficult.
Pfizer News
0Q1N FAQ
What was Pfizer’s price range in the past 12 months?
Pfizer lowest share price was $21.83 and its highest was $30.44 in the past 12 months.
What is Pfizer’s market cap?
Pfizer’s market cap is $169.85B.
When is Pfizer’s upcoming earnings report date?
Pfizer’s upcoming earnings report date is Nov 03, 2026 which is in 5 days.
How were Pfizer’s earnings last quarter?
Pfizer released its earnings results on Aug 04, 2026. The company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.682 by $0.088.
Is Pfizer overvalued?
According to Wall Street analysts Pfizer’s price is currently Undervalued.
Does Pfizer pay dividends?
Pfizer does not currently pay dividends.
What is Pfizer’s EPS estimate?
Pfizer’s EPS estimate is 0.73.
How many shares outstanding does Pfizer have?
Pfizer has 5,699,674,000 shares outstanding.
What happened to Pfizer’s price movement after its last earnings report?
Pfizer reported an EPS of $0.77 in its last earnings report, beating expectations of $0.682. Following the earnings report the stock price went up 2.046%.
Which hedge fund is a major shareholder of Pfizer?
Currently, no hedge funds are holding shares in GB:0Q1N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pfizer Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$29.62 (5.37% Upside)
$29.62 (5.37% Upside)
Blogger Sentiment
Bullish
GB:0Q1N Sentiment 84%
Sector Average 65%
Sector Average 65%
Insider Transactions
Bought Shares
Worth $2.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.74%
12-Months-Change
Fundamentals
Return on Equity
4.89%
Trailing 12-Months
Asset Growth
-2.41%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Pfizer
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
0Q1N Company Deck
0Q1N Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive operational and strategic narrative: management beat Q2 revenue and adjusted EPS expectations, raised full-year revenue guidance, highlighted strong growth across launched and acquired products (notably Seagen assets, Padcev, NURTEC, and Eliquis), and outlined robust R&D progress (numerous readouts, pivotal starts and promising clinical data across obesity, oncology and immunology). At the same time, material near-term setbacks were disclosed: a Phase III SV miss that drove a $4.3 billion impairment and a GAAP loss, lower-than-expected COVID revenues (notably Paxlovid), removal of Oxbryta revenue from forecasts, and elevated near-term R&D spend. Management emphasized cost-savings initiatives (now targeting ~ $9.7B through 2029), maintained dividend commitments, and raised confidence in returning to growth by the end of the decade. Overall, positives (revenue/EPS beats, guidance raise, strong launched/acquired product growth, and significant pipeline progress) outweigh the material but specific negatives tied largely to one clinical readout and COVID variability.View all GB:0Q1N earnings summaries0Q1N Revenue Breakdown
97.79% Biopharma
0.00% PC1
0.00% Pfizer Ignite
2.21% Other business activities
0Q1N Stock 12 Month Forecast
Average Price Target
$29.62
▲(5.37% Upside)